Issue link: https://www.e-digitaleditions.com/i/1526741
14 BioPharm International ® Emerging Therapies eBook September 2024 www.biopharminternational.com Page Header_ profiles against all the masses under the peaks, en- abling easy and precise determination of whether a C-terminal lysine was present on the basic peak. They were also able to examine the acidic proteoform and identify whether it was due to glycation (see Figure 3) (8–10). Knowledge of a higher glycation level in that acidic species could then be used to inform adjust- ments in the feeding processes in the bioreactor to improve product quality. Overcoming challenges in charge variant analysis of ADCs As biopharmaceutical products become more com- plex, such as those involving multispecific antibodies or ADCs, the analytical challenges and need for pre- cise monitoring of PQAs intensif y. ADCs consist of a mAb linked to a cytotoxic drug, introducing addi- tional heterogeneity due to the conjugation process. The analysis of these complex molecules requires advanced techniques to resolve and identify charge variants accurately. One presented example from a team at AstraZen- eca encountered unexpected charge profiles in their icIEF analysis of an ADC, which indicated potential instability and the presence of unanticipated PTMs. By employing an integrated system for icIEF-UV/MS analysis, the team achieved rapid identification of charge variants (3,12) and were able to attribute the change in profile to ring opening events. This system streamlined the separation, quantitation, and iden- tification processes, enabling real-time correlation of pI and mass profiles and ensuring all peaks were accounted for by MS. Genetic variants and early detection In one particularly notable application, Nields' team at Johnson & Johnson identified a genetic sequence vari- ant in one of their top clone selections. This variant, which could have caused significant downstream is- sues, was detected early using the integrated icIEF-UV/ MS approach. By catching this mutation early, the team was able to devise a mitigation strategy and proceed with regulatory discussions proactively, thereby saving significant time and resources (8–10). Orthogonal approaches and future applications The use of integrated CE–MS platforms can signifi- cantly accelerate CLD timelines and enhance data accuracy. The ability to combine icIEF with MS de- tection allows for the simultaneous acquisition of multiple critical data points, providing a more com- prehensive understanding of PTMs and charge vari- ants. Combining icIEF–UV/MS with other analytical techniques such as peptide mapping, intact mass analysis, and size exclusion chromatography (SEC) offers a comprehensive approach to characterize and ensure the stability of biologics. This orthogonal ap- proach enhances the detection of PTMs and genetic variants, ensuring only the highest quality clones are selected for further development. Moreover, technologies such as tunable electron-ac- tivated dissociation (EAD) tandem MS (MS/MS) offer enhanced characterization capabilities for complex biotherapeutics. EAD's tunable energy settings facili- tate detailed analysis of lipid impurities, glycopeptides, and other PTMs, which are crucial for ensuring product stability and safety (7–9,13,14). For instance, in the detection of AGEs through the assessment of potential discoloration of the final prod- uct, the color of protein therapeutics and its changes can be CQAs. Using a multi-attribute methodology (MAM) integrated with EAD-based workf lows, researchers can identify and monitor AGEs that may cause color changes, for example. This detection would enable the development team to refine cell culture conditions and improve overall product quality (7,9). Looking forward, the integration of icIEF–UV/MS analysis into broader CLD workflows promises to fur- ther reduce costs and accelerate timelines. By continu- ally monitoring and adjusting for charge heterogeneity throughout process improvements, researchers can maintain high product quality and stability. Future appli- cations might include middle-down analysis for site-spe- cific PTM characterization, potentially enabling genetic engineering to eliminate unwanted modifications (8,9). Conclusion In the fast-paced and demanding field of biopharma- ceutical development, the ability to optimize cell lines rapidly and early during the drug development process is critical. The integration of advanced analytical tech- nologies, such as icIEF–UV/MS, provides the develop- mental sensitivity, resolution, and speed required to precisely navigate the complexity of therapeutic for- mats, identify potential issues, and inform decisions early in the drug development process. By integrating icIEF–UV/MS into CLD workflows, drug developers can catch and address data inconsistencies early, identify PTMs, and optimize conditions for cell line stability to ensure the selection of the most stable and productive cell lines for therapeutic molecule production. By adopting these advanced analytical methods, biopharmaceutical companies can improve product quality and manufacturing efficiency, ultimately en- hancing drug safety and efficacy. This proactive ap- proach in CLD not only accelerates the development process but also contributes to ensuring the produc- tion of high-quality therapeutic molecules, meeting the growing demands of complex biologics. Streamlined development and production processes should also deliver timeline and cost efficencies as well as ensure that emerging next-generation therapeutics reach the market and clinic faster. Cell Line Development